89987-06-4

Basic information

• Product Name: Tiludronic acid
• Synonyms: [[(4-Chlorophenyl)thio]methylene]bisphosphonic acid;ACPMD;C1-TMBP;ME-3737;C08141;[[(4-Chlorophenyl)thio]methylene]bisphosphonic acid disodium salt hydrate;Tiludronate disodium salt hydrate;Tiludronic acid disodium
• CAS NO: 89987-06-4
• Molecular Formula: C7H9ClO6P2S
• Molecular Weight: 318.61
• Product Categories: API
• Mol File: 89987-06-4.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 600.7°C at 760 mmHg
• Flash Point: 317.1°C
• Appearance: white to off-white/
• Density: 1.82g/cm³
• Vapor Pressure: 2.79E-15mmHg at 25°C
• Refractive Index: 1.652
• Storage Temp.: room temp
• Solubility: H2O: >10mg/mL, clear
• PKA: pK1 10.85; pK2 6.90; pK3 2.95; pK4 1.30(at 25℃)
• CAS DataBase Reference: Tiludronic acid(CAS DataBase Reference)
• NIST Chemistry Reference: Tiludronic acid(89987-06-4)
• EPA Substance Registry System: Tiludronic acid(89987-06-4)

Safety Data

• WGK Germany: 3
• Hazardous Substances Data: 89987-06-4(Hazardous Substances Data)

Usage

Veterinary Drugs and Treatments

Tiludronate disodium (tiludronic acid) is a bisphosphonate bone resorption inhibitor that is available in some countries for the intravenous treatment of navicular disease in horses. Treatment earlier in the course of the disease apparently results in greater efficacy. For humans, there is an orally administered FDA-approved product for treating Paget’s disease (osteitis deformans).

InChI:InChI=1/C7H9ClO6P2S/c8-5-1-3-6(4-2-5)17-7(15(9,10)11)16(12,13)14/h1-4,7H,(H2,9,10,11)(H2,12,13,14)

Upstream product

• 1142-19-4 4,4'-dichlorodiphenyl disulfide 

Relevant articles and documents

Bisphosphonate-Generated ATP-Analogs Inhibit Cell Signaling Pathways

Bisphosphonates are a major class of drugs used to treat osteoporosis, Paget's disease, and cancer. They have been proposed to act by inhibiting one or more targets including protein prenylation, the epidermal growth factor receptor, or the adenine nucleotide translocase. Inhibition of the latter is due to formation in cells of analogs of ATP: the isopentenyl ester of ATP (ApppI) or an AppXp-type analog of ATP, such as AMP-clodronate (AppCCl2p). We screened both ApppI as well as AppCCl2p against a panel of 369 kinases finding potent inhibition of some tyrosine kinases by AppCCl2p, attributable to formation of a strong hydrogen bond between tyrosine and the terminal phosphonate. We then synthesized bisphosphonate preprodrugs that are converted in cells to other ATP-analogs, finding low nM kinase inhibitors that inhibited cell signaling pathways. These results help clarify our understanding of the mechanisms of action of bisphosphonates, potentially opening up new routes to the development of bone resorption, anticancer, and anti-inflammatory drug leads.

Regimen for treatment or prophylaxis of osteoporosis

Methods for treating or preventing osteoporosis, including regimens for intermittent dosing of bone resorption inhibiting polyphosphonate compound or a pharmaceutically acceptable salt or ester of any such compound.